Skip to main content

Advertisement

Fig. 5 | Cancer Communications

Fig. 5

From: Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma

Fig. 5

Mini PDX responses to chemotherapeutic and targeted regimens. Growth of mini-PDX from the patient in mice treated with vehicle, irinotecan, oxaliplatin, nab-paclitaxel, capecitabine, everolimus, S-1, gemcitabine plus cisplatin and S-1 plus cisplatin. One day after tumor cell inoculation, drug treatments commenced. Data show relative tumor cell proliferative rates versus the day 7 vehicle group

Back to article page